ABSTRACT
PURPOSE: We evaluated the diagnostic performance of a noninvasive bladder cancer test, the urinary bladder cancer (UBC) antigen test, on voided urine samples from patients with active transitional cell carcinomas, on follow-up and controls. MATERIALS AND METHODS: We measured the UBC antigen in the urine from 136 patients with active transitional cell carcinomas of the bladder (group 1), 56 patients with no evidence of tumor recurrence, confirmed by cystoscopy at follow-up (group 2), 60 patients with urinary tract infections (group 3), 52 patients with other genitourinary tract malignancies (group 4) and 74 healthy subjects, free from urological diseases (group 5). RESULTS: The mean UBC antigen concentrations were 75.79, 28.95, 52.90, 16.90 and 7.56micro gram/L, in groups 1 to 5, respectively. Group 2, 4 and 5 showed statistically significant differences in the UBC concentrations compared to group 1 (p=0.03, <0.001 and <0.001, respectively). Sensitivity and specificity were 61.8 and 68.2%, at a threshold value of 9.7micro gram/L, from group 1, compared to groups 2 to 5. As for the tumor grade in group 1, there were significant differences between grade I and II (p<0.001) or between grade I and III (p<0.001), but there were no significant differences according to the T stage. CONCLUSIONS: The UBC test might have a role as a potential tumor marker for the diagnosis of transitional cell carcinomas of the bladder adjunct to cystoscopy.
Subject(s)
Humans , Carcinoma, Transitional Cell , Cystoscopy , Diagnosis , Follow-Up Studies , Keratins , Recurrence , Sensitivity and Specificity , Biomarkers, Tumor , Urinary Bladder Neoplasms , Urinary Bladder , Urinary Tract Infections , Urologic DiseasesABSTRACT
PURPOSE: We evaluated the diagnostic performance of a noninvasive bladder cancer test, the urinary bladder cancer (UBC) antigen test, on voided urine samples from patients with active transitional cell carcinomas, on follow-up and controls. MATERIALS AND METHODS: We measured the UBC antigen in the urine from 136 patients with active transitional cell carcinomas of the bladder (group 1), 56 patients with no evidence of tumor recurrence, confirmed by cystoscopy at follow-up (group 2), 60 patients with urinary tract infections (group 3), 52 patients with other genitourinary tract malignancies (group 4) and 74 healthy subjects, free from urological diseases (group 5). RESULTS: The mean UBC antigen concentrations were 75.79, 28.95, 52.90, 16.90 and 7.56micro gram/L, in groups 1 to 5, respectively. Group 2, 4 and 5 showed statistically significant differences in the UBC concentrations compared to group 1 (p=0.03, <0.001 and <0.001, respectively). Sensitivity and specificity were 61.8 and 68.2%, at a threshold value of 9.7micro gram/L, from group 1, compared to groups 2 to 5. As for the tumor grade in group 1, there were significant differences between grade I and II (p<0.001) or between grade I and III (p<0.001), but there were no significant differences according to the T stage. CONCLUSIONS: The UBC test might have a role as a potential tumor marker for the diagnosis of transitional cell carcinomas of the bladder adjunct to cystoscopy.
